FDA Approves Generic Form of Rivaroxaban for CAD and PAD
The US Food and Drug Administration (FDA) recently approved the first generic versions of the anticoagulant rivaroxaban, marketed as Xarelto, to reduce the risk of major cardiovascular events in adults with coronary artery disease (CAD) and major thrombotic vascular events in adults with peripheral artery disease (PAD).
The US Food and Drug Administration (FDA) recently approved the first generic versions of the anticoagulant rivaroxaban, marketed as Xarelto, to reduce the risk of major cardiovascular events in adults with coronary artery disease (CAD) and major thrombotic vascular events in adults with peripheral artery disease (PAD).
